Nano Cannabinoid technology has emerged as the industry’s greatest innovative product which will let the users experience the effects of cannabinoids in one minute or less. Cannabinoids like THC and CBD are turned into nano-sized particles and these microscopic cannabinoids can move quickly through membranes and directly into the bloodstream. Nano Cannabinoids can be experienced instantly (within 45-65 seconds) as the medicine requires no digestion -simple absorption. Skipping the digestion process will make the cannabinoids more active and the user will require less to feel its effects.
Brain diseases cause a major challenge as brain drug delivery is hampered by the blood-brain barrier. The blood-brain barrier (BBB) comprises of the endothelium of the brain’s capillaries. Therefore, there is an imminent necessity for developing an effective brain drug delivery strategy that tackles the biodistribution limitations that results in treatment failure. In this context, targeted drug nanocarriers emerge as an option to attain efficient transport across the brain endothelium following minimally-invasive intravenous injection. In this study, it has been demonstrated that both the brain and glioma targeting ability and drug release rate can be adjusted or tailored by altering the particle size of the nanocapsules. This fine size-tailoring can be attained by the phase inversion temperature method.
The said study has introduced an innovative brain tumor-targeting strategy with cannabidiol (CBD) and on the other hand, nanocapsules as extended-release carriers of cannabidiol to resolve it’s delivery and formulation problems that have normally limited its therapeutic potential. All-in-all small lipid nanocapsules loaded and made functional with cannabidiol emerge as promising dually-targeted contenders for intravenous treatment of glioma.
One of the main features that affect the in vivo behavior of nanocarriers is the size of the particle as their effect primarily depends on the rare interactions of materials at the nanoscale with biological structures. Brain targeting should not exclusively depend on passive targeting. As an alternative, brain active targeting is being explored to improve the transcellular delivery potential of nanocarriers across the BBB.